MarketLens
Sign Up

What's Behind Corcept's Recent Legal Troubles

7 months ago
SHARE THIS ON:

What's Behind Corcept's Recent Legal Troubles

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•3 weeks ago

Corcept Announces Planned Leadership Transition

Corcept Therapeutics announced the retirement of Sean Maduck, President of its Endocrinology division, effective October. Justin Gunn will succeed him and fully assume the role starting October.
Stock News•1 months ago

Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?

Corcept (CORT) shares fell 1.2% in the 30 days since its last earnings report, as investors weigh the company's financial results and near-term outlook.
Stock News•3 months ago

Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook

A Corcept insider sold shares for $1.9M at ~$93.13 each on July 7, after an FDA approval and a $1.05B outlook.

Breaking News

View All →

Top Headlines

View More →
Stock News•28 minutes ago

Microsoft AI chief says the company beat OpenAI at its own game, using a quarter of the computing power

Stock News•30 minutes ago

Google warns suspected China-linked hackers could exploit BeyondTrust flaw

Stock News•1 hour ago

Tesla's Energy Boss Leaves the Company

Stock News•2 hours ago

Why This Market Washout Will Spark a Year-End Rally

Stock News•2 hours ago

Here Are the 3 Magnificent Seven Stocks I'd Buy Today